Effectiveness of Injectable Ibuprofen Salts and Indomethacin to Treat Patent Ductus Arteriosus in Preterm Infants: Observational Cohort Study

Deonne Dersch-Mills, Belal Alshaikh, Amuchou S Soraisham, Albert Akierman, and Kamran Yusuf

ABSTRACT

Background: There is no injectable ibuprofen product marketed to treat patent ductus arteriosus (PDA) in newborns in Canada. The authors’ institution has used ibuprofen arginine in the past. In the absence of published evidence supporting use of this salt form of ibuprofen for neonatal PDA, a retrospective analysis was undertaken.

Objective: To compare the effectiveness and adverse effects of ibuprofen arginine, ibuprofen tromethamine, and indomethacin in the treatment of PDA.

Methods: This retrospective observational cohort study, for patients admitted between 2009 and 2015, included preterm infants with symptomatic PDA who received at least one dose of injectable indomethacin, ibuprofen tromethamine, or ibuprofen arginine. Three effectiveness end points were analyzed: closure after one course of treatment, repeat medical treatment, and surgical ligation. The secondary end points included acute kidney injury, necrotizing enterocolitis, chronic lung disease, and time to full enteral feeding.

Results: A total of 179 infants were included. There were no differences among groups in terms of closure after one course of treatment (37/54 [69%] with indomethacin, 42/70 [60%] with ibuprofen tromethamine, and 28/55 [51%] with ibuprofen arginine; \( p = 0.21 \)) or surgical ligation (10/54 [19%] with indomethacin, 13/70 [19%] with ibuprofen tromethamine, and 12/55 [22%] with ibuprofen arginine; \( p = 0.88 \)). However, there was a difference regarding use of a repeat course of treatment, ibuprofen arginine having the highest rate (8/54 [15%] with indomethacin, 18/70 [26%] with ibuprofen tromethamine, and 20/55 [36%] with ibuprofen arginine; \( p = 0.04 \)). After adjustment for gestational age, the association between ibuprofen arginine and increased use of a repeat course of treatment remained significant. The groups did not differ with respect to adverse effects.

Conclusion: These results highlight the potential for differences in effectiveness among various salt forms of injectable ibuprofen and indomethacin. Because of the small sample size and retrospective methodology, confirmation of the present results through a larger prospective study is needed.

RÉSUMÉ

Contexte : Il n’y a pas sur le marché de produit injectable à base d’ibuprofène pour traiter la persistance du canal artériel (PCA) chez le nouveau-né au Canada. L’ibuprofène arginine a été utilisé auparavant dans l’établissement de santé des auteurs. En l’absence de données publiées appuyant l’utilisation de ce médicament sous forme de ce sel pour traiter la PCA chez le nouveau-né, une analyse rétrospective a été réalisée.

Objectif : Comparer l’efficacité et les effets indésirables de l’ibuprofène arginine, de l’ibuprofène trométhamine et de l’indométhacine dans le traitement de la PCA.

Méthodes : Cette étude de cohorte observationnelle rétrospective, au sujet de patients hospitalisés entre 2009 et 2015, incluait des nourrissons prématurés atteints d’une PCA symptomatique ayant reçu par injection au moins une dose d’indométhacine, d’ibuprofène trométhamine ou d’ibuprofène arginine. Trois paramètres d’évaluation de l’efficacité ont été analysés : la fermeture après un seul traitement, la répétition du traitement médical et la ligature chirurgicale. Les paramètres d’évaluation secondaires étaient les cas d’insuffisance rénale aiguë, d’entérocolite nécrosante et de maladie pulmonaire chronique ainsi que le temps pour atteindre l’alimentation entérale complète.

Résultats : Au total, 179 nourrissons ont été admis à l’étude. Aucune différence n’a été relevée entre les groupes en ce qui touche à la fermeture après un seul traitement (37/54 [69%] pour l’indométhacine, 42/70 [60%] pour l’ibuprofène trométhamine et 28/55 [51%] pour l’ibuprofène arginine; \( p = 0,21 \)) ou à la ligature chirurgicale (10/54 [19%] pour l’indométhacine, 13/70 [19%] pour l’ibuprofène trométhamine et 12/55 [22%] pour l’ibuprofène arginine; \( p = 0,88 \)). Cependant, une différence a été observée pour ce qui est de la répétition du traitement et l’ibuprofène arginine a obtenu le taux le plus élevé (8/54 [15%] pour l’indométhacine, 18/70 [26%] pour l’ibuprofène trométhamine et 20/55 [36%] pour l’ibuprofène arginine; \( p = 0,04 \)). Après ajustement pour l’âge gestationnel, l’association entre l’utilisation de l’ibuprofène arginine et une augmentation du recours à un second traitement demeurait significative. Il n’y avait pas de différence entre les groupes en ce qui touche aux effets indésirables.
Keywords: ductus arteriosus, patent; infant, newborn; indomethacin; ibuprofen; ibuprofen arginine

**Can J Hosp Pharm. 2018;71(1):22-8**

**INTRODUCTION**

About 55% of infants born with body weight less than 1000 g have a symptomatic patent ductus arteriosus (PDA) requiring medical treatment.1,2 A persistent PDA can lead to undesirable pulmonary, renal, and gastrointestinal (GI) effects, thus warranting medical or surgical treatment.3-5 A 2010 meta-analysis reported that ibuprofen was as effective as indomethacin in closing a PDA and reduced the risk of necrotizing enterocolitis (odds ratio [OR] 0.68) and renal insufficiency (OR 0.28 for urine output declining to < 1 mL/kg per hour) relative to indomethacin.6,7

Until early 2010, indomethacin was the sole treatment option for PDA at the Foothills Medical Centre, a 39-bed level 3 neonatal intensive care unit (NICU) in Calgary, Alberta. At that time, a shortage of indomethacin led to use of injectable ibuprofen, which is available in various salt forms. Starting in 2010, ibuprofen tromethamine was obtained through Health Canada’s Special Access Programme and was used for PDA treatment in the unit. From 2011 to 2013, both indomethacin and ibuprofen tromethamine were available and used for this purpose. In 2013, ibuprofen arginine came onto the Canadian market; given its apparently more reliable availability and lower cost, it was adopted as first-line treatment for symptomatic PDA. Of note, the salt form used in most initial ibuprofen efficacy trials has been ibuprofen lysine, which is available in the United States and Europe.8-10 Although many studies do not indicate the salt form of injectable ibuprofen used, ibuprofen tromethamine11-18 and ibuprofen arginine19 have also been studied.

Although the efficacy and safety of ibuprofen for treatment of PDA in neonates has been well described, published data on use of the arginine salt of this drug are limited to a single abstract.19 A difference in pharmacological activity between salt forms is not expected, given that salts of the various ibuprofen products deliver similar amounts of ibuprofen (amount of ibuprofen in 10 mg of salt forms: lysine, 0.028 mmol; tromethamine, 0.030 mmol; arginine, 0.026 mmol). However, data on the use of ibuprofen tromethamine has indicated higher rates of necrotizing enterocolitis relative to placebo, and 3 cases of pulmonary hypertension have been reported.17 These adverse effects are postulated to be related to the timing of administration of ibuprofen tromethamine (< 6 h from birth) or to an effect of the tromethamine buffer.10 Arginine is a precursor of nitric oxide (NO), and ibuprofen arginine has been shown to release NO in animal models. The role of NO in ductal patency has been demonstrated in animal models, and use of an NO synthase inhibitor in combination with indomethacin was associated with improved ductal closure rates in premature newborns relative to indomethacin alone.20-23 These data provide a theoretical reason to doubt the effectiveness of ibuprofen arginine for PDA. In addition, a previous study that compared the effectiveness of ibuprofen arginine and indomethacin in preterm neonates demonstrated that ibuprofen arginine had a significantly lower closure rate after one course (37% versus 65%, p = 0.006) and a higher PDA ligation rate (15% versus 2%, p = 0.03).19 For these reasons, an audit of the effectiveness of ibuprofen arginine for treatment of PDA was deemed prudent.

The objective of this study was to compare the effectiveness of ibuprofen arginine with that of indomethacin and ibuprofen tromethamine in terms of the following outcomes:

- closure of the PDA during initial course of medical therapy;
- failure of initial course of medical therapy, necessitating a repeat course of medical therapy;
- failure of medical treatment, necessitating surgical ligation of the PDA.

The secondary objectives were to compare the incidence of adverse effects of PDA treatment (GI bleeding, spontaneous intestinal perforation, acute kidney injury) and the incidence of necrotizing enterocolitis and chronic lung disease among the 3 groups.

**METHODS**

This retrospective, observational cohort study included all infants at the Foothills Medical Centre NICU with gestational...
age less than 32 weeks and/or birth weight less than 1500 g who had symptomatic PDA requiring pharmacological intervention and received at least one dose of a study drug during the following 3 periods: March 2009 to February 2010 (the indomethacin cohort), March 2010 to February 2011 (the ibuprofen tromethamine cohort), and June 2013 to January 2015 (the ibuprofen arginine cohort). Infants with ductal dependent heart disease, major congenital anomalies, or a contraindication to ibuprofen or indomethacin (urine output < 1 mL/h in the preceding 12 h, serum creatinine > 120 µmol/L, platelet count < 60 × 10⁹/L, presence of necrotizing enterocolitis, or active bleeding) were excluded. Waiver of consent and the full protocol were approved by the University of Calgary Conjoint Health Research Ethics Board.

The computerized order entry system was used to identify infants who received ibuprofen or indomethacin during the 3 study periods. Medical records were reviewed for relevant data. Patients were followed until death or discharge from the NICU.

The decision to treat a PDA was based on clinical signs and symptoms, supplemented by echocardiography confirmation of a hemodynamically significant PDA. Indomethacin (Indocid P.D.A., Merck Frosst Canada) was given in 3 doses (if < 48 h of life, doses of 0.2, 0.1, and 0.1 mg/kg; if 2–7 days of life, doses of 0.2, 0.2, and 0.2 mg/kg; and if > 7 days of life, doses of 0.2, 0.25, and 0.25 mg/kg) at 12-h intervals. Ibuprofen tromethamine (Pedea, Orphan Europe SARL) was given in 3 doses (10, 5, and 5 mg/kg, respectively) at 24-h intervals. Data from these 2 groups of patients had been collected previously and formed the historical comparator groups for this study. Ibuprofen arginine (Caldolor, Alveda Pharmaceuticals) was used at the same dosage as ibuprofen tromethamine.

All infants receiving these agents were monitored clinically and biochemically to look for ductal closure and possible medication-related side effects. In cases of persistent hemodynamically significant PDA (as documented by echocardiography), a repeat course of either agent was used unless contraindicated. Surgical ligation of PDA was considered for those with failure of 2 courses of pharmacological therapy and those with contraindications to the medications.

The primary outcome was effectiveness of treatment, as defined by the following criteria:
• closure of the PDA during the initial course of medical therapy (as confirmed by echocardiography or determined by clinical resolution of symptoms);
• failure of initial course of medical therapy, necessitating a repeat course;
• failure of treatment, necessitating surgical ligation of the PDA.

The following secondary end points were also assessed:
• GI bleeding;
• spontaneous intestinal perforation;
• necrotizing enterocolitis stage II or greater (based on modified Bells staging)³⁻⁵;
• acute kidney injury (urine output < 0.5 mL/kg per hour for more than 8 h or increase in serum creatinine > 30 µmol/L within 72 h of medication administration or ≥ 50% from baseline)³⁶;
• diagnosis of chronic lung disease (oxygen requirement at 36 weeks corrected gestational age);
• age (days of life) when full enteral feeding was achieved.

Descriptive statistics (means and proportions) were used to describe the 3 study groups. Categorical variables were compared among the groups using the χ² test or the Fisher exact test, with a priori significance level of 0.05. Continuous variables were compared using analysis of variance. Patients with missing data were excluded from analysis for the applicable variable; hence, the sample size was reduced for some end points. To account for differences in baseline characteristics and other confounding factors, multivariable logistic regression was used to determine the influence of covariates on the study end points. Factors that differed among groups at a significance level of p < 0.1 in the bivariate analysis and those with a known association with PDA were considered for inclusion in the model.

RESULTS

The ibuprofen arginine cohort had lower mean birth weight (p = 0.001) and appeared to be more acutely ill than the other cohorts, with lower 5-minute APGAR scores (p = 0.012), higher SNAP-II scores (Score for Neonatal Acute Physiology) (p < 0.001), and a higher rate of antenatal steroid use (p = 0.008) (Table 1).

There were no significant differences among the groups in terms of complete or clinical PDA closure after one course of treatment (p = 0.21) and need for PDA ligation (p = 0.88) (Table 2). However, there was a difference in terms of need for a repeat course of medical treatment, the ibuprofen arginine group having a significantly higher rate than the other groups (p = 0.04). A post hoc analysis was performed on the proportion of patients who received both a repeat course of treatment and ligation surgery, but there was no significant difference among the groups (p = 0.34).

There did not appear to be any differences among the groups in terms of incidence of acute kidney injury; however, for this variable there was a high proportion of missing data for the ibuprofen arginine cohort (Table 2). Similarly, no differences were seen regarding incidence of necrotizing enterocolitis, chronic lung disease, time to achieve full enteral feeding, or death before NICU discharge. Because of low event rates, statistical analysis was not performed for the incidence of GI bleeding (n = 2 in indomethacin group, n = 4 in ibuprofen tromethamine group, n = 0 in ibuprofen arginine group) or intestinal perforation (n = 0 in indomethacin group, n = 1 in ibuprofen tromethamine group, n = 4 in ibuprofen arginine group).
**DISCUSSION**

In this retrospective analysis, the agent used for PDA treatment did not appear to affect the rate of clinical or complete closure after the initial course of treatment or the need for surgical ligation, which was reassuring. However, use of ibuprofen arginine appeared to be associated with greater use of repeat treatment courses. Given the similar quantity of ibuprofen delivered from its various salts, and meta-analytic data supporting similar efficacy between other ibuprofen salts and indomethacin, this result was unexpected.

Potential explanations for this unexpected finding include the release of NO by ibuprofen arginine. Although release of NO could theoretically reduce the effectiveness of ibuprofen arginine in PDA treatment, the amount of arginine provided through therapeutic doses of this agent is very low (0.024 mmol/kg daily; dose for prevention of necrotizing enterocolitis 1.5 mmol/kg daily). It is possible that this is the explanation for the increased need for repeat courses of treatment, and that this study was too small to show differences in the other effectiveness end points. The closure rate was numerically lower with ibuprofen arginine (51%) than with indomethacin (69%) and ibuprofen tromethamine (60%), although the comparison did not reach statistical significance.

A more likely explanation is that these findings represent biases in practice. Given the study’s retrospective and uncontrolled design, there was no standard decision-making model for initiation of medical treatment for PDA or for repetition of the course of treatment. The greater use of repeat courses of treatment with ibuprofen arginine could reflect increased clinician comfort with ibuprofen over indomethacin because of its more favourable safety profile. The ibuprofen arginine cohort was the most recent cohort, and comfort with ibuprofen’s safety profile may have been building over time. Greater use of repeat medical treatment with ibuprofen arginine could also represent growing skepticism toward ibuprofen’s efficacy among neonatologists, which is supported by subjective observations at our centre. This skepticism may have influenced clinicians’ decisions about whether or not an infant would benefit from a repeated course of treatment.

The results for closure and ligation rates reported here differ from those reported in the only other study examining use of ibuprofen arginine for PDA in preterm neonates. That study
arginine had significantly lower closure rates after one course of treatment (37% with ibuprofen arginine versus 65% with indomethacin, \( p = 0.06 \)) and a higher PDA ligation rate (15% with ibuprofen arginine versus 2% with indomethacin, \( p = 0.03 \)). The differences observed here were much smaller (for closure, 51% with ibuprofen arginine versus 69% with indomethacin, \( p = 0.21 \); for ligation, 22% with ibuprofen arginine versus 19% with indomethacin, \( p = 0.88 \)). These differences could reflect differences in selection of patients for medical treatment.

\( n = 86 \) patients reported that patients treated with ibuprofen arginine had significantly lower closure rates after one course of treatment (37% with ibuprofen arginine versus 65% with indomethacin, \( p = 0.06 \)) and a higher PDA ligation rate (15% with ibuprofen arginine versus 2% with indomethacin, \( p = 0.03 \)). The differences observed here were much smaller (for closure, 51% with ibuprofen arginine versus 69% with indomethacin, \( p = 0.21 \); for ligation, 22% with ibuprofen arginine versus 19% with indomethacin, \( p = 0.88 \)). These differences could reflect differences in selection of patients for medical treatment.

### Table 2. Outcomes by Treatment Group

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Indomethacin (n = 54)</th>
<th>Ibuprofen Tromethamine (n = 70)</th>
<th>Ibuprofen Arginine (n = 55)</th>
<th>( p ) Value†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at start of treatment (days of life) (mean ± SD)</td>
<td>3.7 ± 2.5</td>
<td>5.5 ± 4.6†</td>
<td>5.6 ± 5.2‡</td>
<td>0.04</td>
</tr>
<tr>
<td>First course of treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Completed</td>
<td>36 (67)</td>
<td>62 (89) ¶</td>
<td>45 (82)</td>
<td>0.01</td>
</tr>
<tr>
<td>Not completed</td>
<td>18 (33)</td>
<td>8 (11)</td>
<td>10 (18)</td>
<td></td>
</tr>
<tr>
<td>Reason for non-completion</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Renal</td>
<td>9 (50)</td>
<td>2 (25)</td>
<td>3 (30)</td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>1 (6)</td>
<td>2 (25)</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Bleeding</td>
<td>2 (11)</td>
<td>1 (13)</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Closure before completion</td>
<td>6 (33)</td>
<td>3 (37)</td>
<td>6 (60)</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>0</td>
<td>0</td>
<td>1 (10)</td>
<td></td>
</tr>
<tr>
<td>Primary end point</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Complete or clinical closure after first course of treatment</td>
<td>37 (69)</td>
<td>42 (60)</td>
<td>28 (51)</td>
<td>0.21</td>
</tr>
<tr>
<td>Received repeat course of treatment</td>
<td>8 (15)</td>
<td>18 (26)</td>
<td>20 (36)**</td>
<td>0.04</td>
</tr>
<tr>
<td>Underwent surgical ligation</td>
<td>10 (19)</td>
<td>13 (19)</td>
<td>12 (22)</td>
<td>0.88</td>
</tr>
<tr>
<td>Received both repeat course of treatment and surgical ligation</td>
<td>4 (7)</td>
<td>8 (11)</td>
<td>9 (16)</td>
<td>0.34</td>
</tr>
<tr>
<td>Secondary end points</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute kidney injury</td>
<td>11 (20)</td>
<td>10/69 (14)</td>
<td>2/10 (10)</td>
<td>0.49</td>
</tr>
<tr>
<td>Necrotizing enterocolitis ≥ stage II</td>
<td>5 (9)</td>
<td>5 (7)</td>
<td>8 (15)</td>
<td>0.38</td>
</tr>
<tr>
<td>Chronic lung disease</td>
<td>27/46 (59)</td>
<td>38/68 (56)</td>
<td>23/42 (55)</td>
<td>0.93</td>
</tr>
<tr>
<td>Age at full enteral feeding (days of life) (mean ± SD)</td>
<td>23.9 ± 11</td>
<td>24.3 ± 10</td>
<td>27.4 ± 16</td>
<td>0.28</td>
</tr>
<tr>
<td>Death before NICU discharge</td>
<td>2 (4)</td>
<td>3 (4)</td>
<td>4 (7)</td>
<td>0.65</td>
</tr>
</tbody>
</table>

**Table 3. Results of Regression Analysis (Relative to Indomethacin Control)**

<table>
<thead>
<tr>
<th>End Point</th>
<th>Ibuprofen Tromethamine</th>
<th>Ibuprofen Arginine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Comparison Group; Adjusted OR* (95% CI)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Closure after first course of treatment</td>
<td>0.75 (0.33–1.71)</td>
<td>0.60 (0.25–1.47)</td>
</tr>
<tr>
<td>Received repeat course of treatment</td>
<td>1.74 (0.60–5.02)</td>
<td>4.25 (1.34–13.4)</td>
</tr>
<tr>
<td>Underwent surgical ligation</td>
<td>0.73 (0.25–2.16)</td>
<td>1.00 (0.31–3.20)</td>
</tr>
</tbody>
</table>

CI = confidence interval, OR = odds ratio.
*Adjusted for gestational age, SNAP-II score, prenatal steroids, chorioamnionitis, and day of life at start of treatment.
and surgical referral, which would be supported by the significantly higher rates of ligation in our cohort. Further support for this theory is difficult to ascertain because the results of the previous study were published in abstract form only.\(^\text{19}\)

Failure rates in both of the current ibuprofen cohorts were higher than what was reported in the meta-analysis (40% with ibuprofen tromethamine and 49% with ibuprofen arginine in the current study versus about 26% in the meta-analysis\(^\text{10}\)). The lower rate reported previously could be related to patient selection, although there has also been some discussion in the literature about the need for higher ibuprofen doses, starting in 2005.\(^\text{20}\)

More recently, in 2012, Dani and others\(^\text{20}\) reported improved rates of PDA closure with an ibuprofen dosing regimen of 20, 10, and 10 mg/kg given at 24-h intervals, with no increase in adverse effects. Use of this higher-dose regimen might improve closure rates seen at our centre, but would need to be evaluated before widespread adoption.

As reported in the meta-analysis,\(^\text{10}\) the rates of acute kidney injury, chronic lung disease, necrotizing enterocolitis, and death in the present cohorts did not differ among treatment groups. However, the current study was likely too small to detect differences in these end points, and missing data because of inconsistent measurement of serum creatinine further reduced the sample size for acute kidney injury. There were no statistically significant differences in rate of necrotizing enterocolitis, although the rate was numerically higher in the ibuprofen arginine group (15% versus 9% with indomethacin and 7% with ibuprofen tromethamine, \(p = 0.38\)). There was also no difference among cohorts in the time needed to reach full enteral feeding, but again this was numerically (if not statistically) higher in the ibuprofen arginine group (27.4 days versus 23.9 with indomethacin and 24.3 days with ibuprofen tromethamine, \(p = 0.28\)). These observations may be due to the younger gestational age and lower birth weight of the ibuprofen arginine group at baseline. The incidence of GI bleeding and intestinal perforation were too low to analyze, and further examination of these outcomes in a larger study may be warranted.

During the periods of ibuprofen tromethamine and indomethacin use that were analyzed in this study, these were the only PDA treatment options available on the units. However, during the period when ibuprofen arginine was used, indomethacin was also available, and oral ibuprofen had become a more frequently used agent for PDA treatment. This difference in clinical context has the potential to confound our end points, as clinician bias may have played a role in selection of the initial agent, as well as the agent used for repeat courses of treatment. For example, 2 patients in the ibuprofen arginine group received indomethacin for their repeat course, and 1 patient in this group received oral ibuprofen.

To our knowledge, this study is the first to compare multiple salts of ibuprofen and indomethacin in terms of the end points of PDA treatment in neonates; however, it was limited by its retrospective observational design. The higher rate of repeat treatment courses with ibuprofen arginine could represent clinician bias in deciding when to use repeat courses, either because of comfort with ibuprofen's safety or skepticism about ibuprofen’s effectiveness. The sample sizes were limited by the timelines for availability of the 3 agents, and the study was therefore too small to show differences in rates of the less common end points (i.e., adverse effects). Overall, confirmation of the present results through a larger prospective study would be ideal. The results would further inform Canadian neonatal clinicians' ability to use a more readily accessible injectable ibuprofen product, rather than one available only through Health Canada's Special Access Programme.

**CONCLUSION**

Ibuprofen arginine has been more accessible and less expensive than other PDA treatment options at the authors’ centre, but the potential for differing effectiveness (based on the theoretical effects of NO and data presented only in abstract form) required that its use be audited before widespread adoption. Other salts of ibuprofen have been shown to have effects similar to those of indomethacin, with evidence of lower rates of necrotizing enterocolitis and renal dysfunction. Our data suggest similar closure rates after one course and similar surgical ligation rates, but an increased need for repeat courses of PDA treatment with ibuprofen arginine. This difference may represent clinician bias in initiating and repeating courses of medical treatment with ibuprofen that have developed over time. No significant differences were observed among the 3 treatments regarding adverse effects. The effectiveness of ibuprofen arginine should be examined in larger cohorts with appropriate randomization and controls.

**References**


Deonne Dersch-Mills, BScPharm, ACPR, PharmD, is with the Inpatient Pharmacy, Alberta Children’s Hospital (Alberta Health Services), Calgary, Alberta.

Belal Alshaikh, MD, is with the Section of Neonatology, Department of Pediatrics, University of Calgary, Calgary, Alberta.

Amuchoo S Saroaisham, MD, is with the Section of Neonatology, Department of Pediatrics, University of Calgary, Calgary, Alberta.

Albert Akierman, MD, is with the Section of Neonatology, Department of Pediatrics, University of Calgary, Calgary, Alberta.

Kamran Yusuf, MD, is with the Section of Neonatology, Department of Pediatrics, University of Calgary, Calgary, Alberta.

Competing interests: None declared.

Address correspondence to: Deonne Dersch-Mills Inpatient Pharmacy Alberta Children’s Hospital 2888 Shaganappi Trail NW Calgary AB T3B 6A8 e-mail: deonne.dersch-mills@ahs.ca

Funding: This study was funded internally by Alberta Health Services Pharmacy Department. There was no external funding or support.

Acknowledgement: The authors wish to thank Jayesh Changela for his work on data collection for this project.